Substance / Medication

Kanamycin

Overview

Active Ingredient
kanamycin
RxNorm CUI
6099

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Diagnosis of Drug Resistance to Fluoroquinolones, Amikacin, Capreomycin, Kanamycin and Ethambutol with Genotype MTBDRsl Assay: a Meta-Analysis.
Mao Xiaolu, Ke Zunqiong, Shi Xiaoyan et al. · Ann Clin Lab Sci · 2015
PMID: 26586705Meta-Analysis
Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options.
Sfoungaristos Stavros, Gofrit Ofer N, Yutkin Vladimir et al. · Expert Opin Pharmacother · 2015
PMID: 25881654Meta-Analysis
Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats.
Rodriguez Salgueiro Sandra, González Núñez Lucía, García Del Barco Herrera Diana et al. · Iran J Kidney Dis · 2014
PMID: 25194405RCT
Strategy to control catheter encrustation with citrated drinks: a randomized crossover study.
Khan Azhar, Housami Fadi, Melotti Roberto et al. · J Urol · 2010
PMID: 20171661RCT
Pathogenesis ofInfection.
Armbruster Chelsie E, Mobley Harry L T, Pearson Melanie M · EcoSal Plus · 2018
PMID: 29424333ReviewFull text (PMC)
From Catheter to Kidney Stone: The Uropathogenic Lifestyle of Proteus mirabilis.
Norsworthy Allison N, Pearson Melanie M · Trends Microbiol · 2017
PMID: 28017513ReviewFull text (PMC)
Microbiological/clinical characteristics and validation of topical therapy with kanamycin in aerobic vaginitis: a pilot study.
Tempera G, Bonfiglio G, Cammarata E et al. · Int J Antimicrob Agents · 2004
PMID: 15225868Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Kanamycin (substance)
SNOMED CT
387396008
UMLS CUI
C0022487
RxNorm CUI
6099

Clinical Data

This intervention maps to 11 entities in the Ltrl knowledge graph.

11
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.